APOA1 hFc Chimera, Human
APOA1 HFc Chimera, Human

The purity of APOA1 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

APOA1 HFc Chimera, Human

APOA1 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

APOA1 hFc Chimera, Human

Apolipoprotein A1 (ApoA1) is a main protein moiety in high-density lipoprotein (HDL) particles. Generally, ApoA1 and HDL are considered as atheroprotective. In prooxidant and inflammatory microenvironment in the vicinity to the atherosclerotic lesion, ApoA1/HDL are subjected to modification. The chemical modifications such as oxidation, nitration, etc result in altering native architecture of ApoA1 toward dysfunctionality and abnormality.
Z05033
¥67,155.00

Ask us a question
Product Introduction
Species Human
Protein Construction
APOA1 (Asp25-Gln267)
Accession # P02647		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 54.8 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • APOA1 HFc Chimera, Human
    • APOA1 HFc Chimera, Human

    The purity of APOA1 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • APOA1 HFc Chimera, Human
    • APOA1 HFc Chimera, Human

    APOA1 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Apolipoprotein A1 (ApoA1) is a main protein moiety in high-density lipoprotein (HDL) particles. Generally, ApoA1 and HDL are considered as atheroprotective. In prooxidant and inflammatory microenvironment in the vicinity to the atherosclerotic lesion, ApoA1/HDL are subjected to modification. The chemical modifications such as oxidation, nitration, etc result in altering native architecture of ApoA1 toward dysfunctionality and abnormality.
Synonyms Apo-AI; ProapoA-I; Apoa1; Apolipoprotein A-I; APOA1; MGC117399; Alp-1; Brp-14; Ltw-1; Lvtw-1; Sep-1; Sep-2

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.